Literature DB >> 15599600

Advances in opioid therapy and formulations.

Declan Walsh1.   

Abstract

Newly developed opioid analgesics and drug delivery systems may provide pain relief for patients intolerant of morphine. Long-acting oral opioids supply satisfactory analgesia at more convenient dosing intervals. Implantable pumps can provide full analgesic doses of opioids both subcutaneously and intrathecally over extended time periods. Optimal opioid use should rely on individualized dose-finding approaches to enhance pain relief while limiting drug-related side effects and avoiding the common problems associated with opioid prescription in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599600     DOI: 10.1007/s00520-004-0743-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  41 in total

Review 1.  Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology.

Authors:  S B Howell
Journal:  Cancer J       Date:  2001 May-Jun       Impact factor: 3.360

Review 2.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.

Authors:  Kyriaki Mystakidou; Sofia Befon; Eleni Tsilika; Kostas Dardoufas; Stavroula Georgaki; Lambros Vlahos
Journal:  Oncology       Date:  2002       Impact factor: 2.935

4.  Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.

Authors:  J O Wong; G L Chiu; C J Tsao; C L Chang
Journal:  Acta Anaesthesiol Sin       Date:  1997-03

5.  Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.

Authors:  L Allan; H Hays; N H Jensen; B L de Waroux; M Bolt; R Donald; E Kalso
Journal:  BMJ       Date:  2001-05-12

6.  Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain.

Authors:  A Broomhead; R Kerr; W Tester; P O'Meara; C Maccarrone; R Bowles; P Hodsman
Journal:  J Pain Symptom Manage       Date:  1997-08       Impact factor: 3.612

Review 7.  Atypical antipsychotics: mechanism of action.

Authors:  Philip Seeman
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

8.  Visual analog pain scores do not define desire for analgesia in patients with acute pain.

Authors:  Howard A Blumstein; Dave Moore
Journal:  Acad Emerg Med       Date:  2003-03       Impact factor: 3.451

9.  Variations in patients' self-report of pain by treatment setting.

Authors:  Cielito C Reyes-Gibby; Linda L McCrory; Charles S Cleeland
Journal:  J Pain Symptom Manage       Date:  2003-05       Impact factor: 3.612

10.  Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.

Authors:  E Bruera; M Belzile; E Pituskin; R Fainsinger; A Darke; Z Harsanyi; N Babul; I Ford
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

View more
  2 in total

Review 1.  Pharmacological management of cancer pain in the elderly.

Authors:  Sebastiano Mercadante; Edoardo Arcuri
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  Effects of different electroacupuncture scheduling regimens on murine bone tumor-induced hyperalgesia: sex differences and role of inflammation.

Authors:  Branden A Smeester; Mona Al-Gizawiy; Alvin J Beitz
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-20       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.